Everest Medicines Ltd. (1952) Financial Statements

4 Followers

Everest Medicines Ltd. Financial Overview

Everest Medicines Ltd.'s market cap is currently HK$13.92B. The company's EPS TTM is HK$-0.13684274159999998; its P/E ratio is -38.53; Everest Medicines Ltd. is scheduled to report earnings on March 25, 2026, and the estimated EPS forecast is HK$-1.05. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	¥ 1.66B	¥ 706.68M	¥ 125.93M	¥ 12.79M	¥ 54.00K
Gross Profit	¥ 998.84M	¥ 528.89M	¥ 91.52M	¥ 8.15M	¥ 31.00K
Operating Income	¥ -376.32M	¥ -1.12B	¥ -932.74M	¥ -256.80M	¥ -1.03B
EBITDA	¥ -223.85M	¥ -670.04M	¥ -744.63M	¥ -198.91M	¥ -972.78M
Net Income	¥ -290.06M	¥ -1.04B	¥ -844.46M	¥ -247.28M	¥ -1.01B
Balance Sheet
Cash & Short-Term Investments	¥ 2.73B	¥ 1.60B	¥ 2.35B	¥ 1.65B	¥ 2.64B
Total Assets	¥ 6.84B	¥ 4.96B	¥ 5.77B	¥ 6.61B	¥ 6.65B
Total Debt	¥ 925.98M	¥ 575.61M	¥ 510.63M	¥ 534.64M	¥ 485.03M
Net Debt	¥ -1.81B	¥ -308.86M	¥ -12.44M	¥ 12.93M	¥ -2.16B
Total Liabilities	¥ 1.53B	¥ 886.05M	¥ 804.10M	¥ 960.25M	¥ 753.83M
Stockholders' Equity	¥ 5.31B	¥ 4.07B	¥ 4.97B	¥ 5.65B	¥ 5.89B
Cash Flow
Free Cash Flow	¥ -172.32M	¥ -744.92M	¥ -1.04B	¥ -1.59B	¥ -1.71B
Operating Cash Flow	¥ -109.96M	¥ -679.51M	¥ -769.19M	¥ -1.16B	¥ -729.94M
Investing Cash Flow	¥ -674.78M	¥ 974.40M	¥ 752.50M	¥ -1.03B	¥ -975.82M
Financing Cash Flow	¥ 1.75B	¥ 37.80M	¥ 10.10M	¥ -25.31M	¥ -76.51M

Currency in CNY

Everest Medicines Ltd. Earnings and Revenue History

Income Statement >

Everest Medicines Ltd. Debt to Assets

Balance Sheet >

Everest Medicines Ltd. Cash Flow

Cash Flow >

Everest Medicines Ltd. Forecast EPS vs Actual EPS

Earnings >